Glucose-lowering medication selection in patients with diabetes and acute cerebrovascular accident
https://doi.org/10.15829/1728-8800-2020-1-2378
Abstract
The review presents the analysis of current approaches to the management of diabetic patients with acute cerebrovascular accident. Based on the results of meta-analyzes, glycemic targets on the first day after acute cerebrovascular accident were determined and management strategy regarding the insulin therapy issue was discussed. The pros and cons of various ways injecting insulin and the prospects for further management of patients with the use of glucose-lowering medications in patients with type 2 diabetes were considered.
About the Authors
O. V. Zanozina
Privolzhsky Research Medical University; N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
Russian Federation
Russian Federation
Nizhny Novgorod
Yu. A. Sorokina
Privolzhsky Research Medical University
Russian Federation
Russian Federation
Nizhny Novgorod
L. V. Lovtsova
Privolzhsky Research Medical University
Nizhny Novgorod
References
1. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by II Dedov, MV Shestakova, AYu Majorov. 9th issue. M.: UP PRINT; 2017. 212 p. (In Russ.) ISBN: 978-5-91487-136-6. doi:10.14341/DM221S1.
2. Bondar IA, Krasnopevtseva IP. Features of the course of acute cerebrovascular accident in type 2 diabetes mellitus. Journal of Siberian Medical Sciences. 2015;(3):45. (In Russ.)
3. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014;130:1532-58. doi:10.1161/CIR.0000000000000094.
4. Tanashyan MM, Antonov KV, Lagoda OV, et al. Acute stroke and type 2 diabetes. Annals of Clinical and Experimental Neurology. 2014;8(3):4-8. (In Russ.) Танашян M. M., Антонова К. В., Лагода О. В. и др. Острые нарушения мозгового кровообращения и сахарный диабет 2 типа. Анналы клинической и экспериментальной неврологии. 2014;8(3):4-8.
5. Chen R, Ovbiagele B, Feng W. Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci. 2016;351(4):380-6. doi:101016/j.amjms.2016.01.011.
6. Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev. 2014;23(1):CD005346. doi:10.1002/14651858.CD005346.pub4.
7. Yatabe T, Inoue S, Sakaguchi M. The optimal target for acute glycemic control in critically ill patients: a network meta-analysis. Intensive Care Med. 2017;43:16-28. doi:10.1007/s00134-016-4558-2.
8. Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020-35. doi:10.1161/STR.0000000000000074.
9. Strongin LG, Grigoryan IG, Gustov AV, et al. Insulin therapy of type 2 diabetes in the acute period of stroke: the value of the method of insulin administration. Problems of endocrinology. 2014;60(5):4-8. (In Russ.) doi:10.14341/probl20146054-8.
10. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032-60. doi:10.1161/STR.0000000000000069.
11. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38-360. doi:10.1161/CIR.0000000000000350.
12. Zhu S, McClure LA, Lau H, et al. A. Recurrent vascular events in lacunar stroke patients with metabolic syndrome and/or diabetes. Neurology. 2015;85:935-94. doi:10.1212/WNL.0000000000001933.
13. Bellolio MF, Gilmore RM, Stead LG. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev. 2011;7(9):CD005346. doi:101002/14651858.CD005346.pub3.
14. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015;3:105-13. doi:10.1016/S2213-8587(14)70219-0.
15. Bangen KJ, Gu Y, Gross AL, et al. Relationship Between Type 2 Diabetes Mellitus and Cognitive Change in a Multiethnic Elderly Cohort. J Am Geriatr Soc. 2015;63:1075-83. doi:10.1111/jgs.13441.
16. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke. 2014;9:246-51. doi:10.1111/ijs.12045.
17. Ntaios G, Papavasileiou V, Bargiota A, et al. Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2014;9:489-93. doi:10.1111/ijs.12225.
18. Drury P, Levi C, D'Este C. Quality in Acute Stroke Care (QASC): process evaluation of an intervention to improve the management of fever, hyperglycemia, and swallowing dysfunction following acute stroke. Int J Stroke. 2014;9:766-76. doi:10.1111/ijs.12202.
19. Koga M, Yamagami H, Okuda S. Blood glucose levels during the initial 72h and 3-month functional outcomes in acute intracerebral hemorrhage: The SAMURAI-ICH study. J Neurol Sci. 2014;350:75-8. doi:10.1016/j.jns.2015.02.018.
20. Clinical guidelines. http://cr.rosminzdrav.ru/#!/schema/146#doc_terms (12 dec 2018). (In Russ.) http://cr.rosminzdrav.ru/#!/schema/146#doc_terms (12.12.2018).
21. European guidelines on cardiovascular disease prevention in clinical practice. 31. Russian Journal of Cardiology. 2017;6(146):7-85. (In Russ.) doi:10.15829/1560-4071-2017-6-7-85.
22. Tyurenkov IN, Kurkin DV, Bakulin DA, et al. Cerebroprotective activity of metformin, gosogliptin, citicoline and a novel GPR119 agonist in cerebral ischemia under experimental diabetes mellitus. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 33. 2017; Special issues. 117( 12):53-9. (In Russ.) doi:10.17116/ jnevro201711712253-59.35.
23. Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez, et al. Antidiabetic drugs and stroke risk. Current evidence. Eur J Intern Med. 2018;48:1-5. doi: 10.1016/j.ejim.2017.09.019.
24. Moriea PI. Metformin in the diabetic brain friend or foe? AnnTransl Med. 2014;2(6):54. doi:10.3978/j.issn.2305-5839.2014.06.10.
25. Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation. 2015;132:691-718. doi:10.2337/dci15-0012.
26. Yaghi S, Furie KL, Viscoli CM, et al. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation. 2018;137(5):455-63. doi:10.1161/CIRCULATIONAHA.117.030458.
27. Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. 2019;76(5):526-35. doi:10.1001/jamaneurol.2019.0079.
28. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patientswith insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and 40. meta-analysis. BMJ Open. 2017;7(1):e013927 doi:10.1136/bmjopen-2016-013927.
29. DeFronzo RA, Inzucchi S, Abdul-Ghani M, et al. Pioglitazone: The forgotten, 41. cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133-43. doi:101177/1479164118825376.
30. Tziomalos K, Bouziana SD, Spanou M, et al. Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus 42. admitted with acute ischaemic stroke. Diab Vasc Dis Res. 2015;12(6):463-6. doi:10.1177/1479164115597867.
31. Chiazza F, Tammen H, Pintana H, et al. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1a/CXCR4 pathway. Cardiovasc Diabetol. 2018;17(1):60. doi:10.1186/s12933-018-0702-3.
32. Hardigan T, Yasir A, Abdelsaid M, et al. Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2016;311(3):R466-77 doi: 10.1152/ajpregu.00057.2016.
33. Liang CY, Chen DY, Mao CT, et al. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study. Medicine (Baltimore). 2018;97(52):e13844. doi:10.1097/MD.0000000000013844. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-42. doi:10.1056/NEJMoa1501352.
34. Barkas F, Elisaf M, Tsimihodimos V, et al. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. Diabetes Metab. 2017;43(1):1-8. doi:10.1016/j.diabet.2016.10.006.
35. Sinha B, Ghosal S, Statescu C, et al. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8-16. doi:10.1016/j.diabres.2019.02.014.
36. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-44. doi:10.1056/NEJMoa1607141.
37. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018;71(23):2628-39. doi:10.1016/j.jacc.2018.03.009.
38. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1580-91. doi:10.1001/jama.2018.3024.
39. Ferrannini E. Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. Cell Metab. 2017;26(1):27-38. doi:10.1016/j.cmet.2017.04.011.
40. Udell JA, Yuan Z, Rush T, et al. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation. 2018;137(14):1450-9. doi:10.1161/CIRCULATIONAHA.117.031227.
41. Avogaro A, Delgado E, Lingvay I. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev. 2018;34(4):e2981. doi:10.1002/dmrr.2981.
Review
For citations:
Zanozina O.V., Sorokina Yu.A., Lovtsova L.V. Glucose-lowering medication selection in patients with diabetes and acute cerebrovascular accident. Cardiovascular Therapy and Prevention. 2020;19(1):94-98. (In Russ.) https://doi.org/10.15829/1728-8800-2020-1-2378
Views:
1187
Email this article 
